Mariana Del Grossi Moura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariana Del Grossi Moura has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Luciane Cruz Lopes
Universidade de Sorocaba
7 shared publications - Cristiane de Cássia Bergamaschi
Graduate Course in Pharmaceutical Sciences University of Sorocaba São Paulo Brazil
6 shared publications - Flavia Casale Abe
Postgraduate Program in Pharmaceutical Sciences - University of Sorocaba, Sorocaba, Brazil
3 shared publications - Luis Phillipe Nagem Lopes
Faculty of Pharmacy Federal University of Rio de Janeiro Rio de Janeiro Brazil
3 shared publications - Alan Maicon de Oliveira
School of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo Ribeirão Preto São Paulo Brazil
2 shared publications - Everton Nunes da Silva
Universidade de Brasília
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 11 (s.4)
AjudAí: inovação digital para gestão colaborativa de medicamentos entre instituições de saúde no Brasil
Introdução (com o objetivo): O desperdício de medicamentos e insumos em serviços de saúde representa um desafio relevante para a gestão de recursos. No Brasil, entre 2019 e 2023, foram descartados aproximadamente R$ 2,2 bilhões em produtos não utilizados dentro do prazo de validade. Esse cenário está associado à coexistência de estoques excedentes e desabastecimento, decorrente de variações na demanda, mudanças em protocolos assistenciais, baixa rotatividade de estoques refletindo ineficiências na gestão e, sobretudo, na falta de mecanismos estruturados de comunicação entre instituições, ainda dependentes de contatos informais, e-mails ou telefonemas. O objetivo deste estudo é apresentar uma solução digital para promover a gestão colaborativa de medicamentos, com foco na redução de desperdícios e na ampliação do acesso entre instituições de saúde. Descrição: Trata-se de um relato de experiência sobre o desenvolvimento do AjudAí, uma plataforma digital que permite o cadastro gratuito de instituições de saúde, incluindo hospitais públicos e privados, secretarias de saúde e farmácias filantrópicas. A ferramenta possibilita a publicação de anúncios de medicamentos disponíveis ou procurados, além da busca ativa por itens, com o objetivo de facilitar trocas, empréstimos ou doações entre instituições. A plataforma estrutura a comunicação entre instituições, substituindo mecanismos informais como contatos pessoais, e-mails ou telefonemas. O sistema permite o cadastro institucional e a publicação de anúncios de medicamentos disponíveis ou demandados, com funcionalidades de busca e visualização de produtos entre diferentes instituições. Entre seus principais atributos, destacam-se a ampliação da rede colaborativa e o acesso a informações atualizadas sobre disponibilidade e necessidade de medicamentos. A plataforma encontra-se ativa, com participação de 85 usuários, distribuídos em 28 municípios de 7 estados brasileiros. A iniciativa demonstra viabilidade prática e potencial para reduzir perdas evitáveis e mitigar desabastecimentos. Conclusão: O AjudAí representa uma inovação digital escalável de apoio à comunicação entre instituições de saúde, permitindo a divulgação estruturada de informações sobre disponibilidade e necessidade de medicamentos e apoiando processos de redistribuição entre serviços. Ao estruturar a comunicação e viabilizar a redistribuição de medicamentos, a plataforma contribui para o uso mais eficiente de recursos públicos e privados, com impacto direto na sustentabilidade e no acesso à assistência farmacêutica.
- 23 September 2026
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 11 (s.4)
Open AccessAjudAí: inovação digital para gestão colaborativa de medicamentos entre instituições de saúde no Brasil
Introdução (com o objetivo): O desperdício de medicamentos e insumos em serviços de saúde representa um desafio relevante para a gestão de recursos. No Brasil, entre 2019 e 2023, foram descartados aproximadamente R$ 2,2 bilhões em produtos não utilizados dentro do prazo de validade. Esse cenário está associado à coexistência de estoques excedentes e desabastecimento, decorrente de variações na demanda, mudanças em protocolos assistenciais, baixa rotatividade de estoques refletindo ineficiências na gestão e, sobretudo, na falta de mecanismos estruturados de comunicação entre instituições, ainda dependentes de contatos informais, e-mails ou telefonemas. O objetivo deste estudo é apresentar uma solução digital para promover a gestão colaborativa de medicamentos, com foco na redução de desperdícios e na ampliação do acesso entre instituições de saúde. Descrição: Trata-se de um relato de experiência sobre o desenvolvimento do AjudAí, uma plataforma digital que permite o cadastro gratuito de instituições de saúde, incluindo hospitais públicos e privados, secretarias de saúde e farmácias filantrópicas. A ferramenta possibilita a publicação de anúncios de medicamentos disponíveis ou procurados, além da busca ativa por itens, com o objetivo de facilitar trocas, empréstimos ou doações entre instituições. A plataforma estrutura a comunicação entre instituições, substituindo mecanismos informais como contatos pessoais, e-mails ou telefonemas. O sistema permite o cadastro institucional e a publicação de anúncios de medicamentos disponíveis ou demandados, com funcionalidades de busca e visualização de produtos entre diferentes instituições. Entre seus principais atributos, destacam-se a ampliação da rede colaborativa e o acesso a informações atualizadas sobre disponibilidade e necessidade de medicamentos. A plataforma encontra-se ativa, com participação de 85 usuários, distribuídos em 28 municípios de 7 estados brasileiros. A iniciativa demonstra viabilidade prática e potencial para reduzir perdas evitáveis e mitigar desabastecimentos. Conclusão: O AjudAí representa uma inovação digital escalável de apoio à comunicação entre instituições de saúde, permitindo a divulgação estruturada de informações sobre disponibilidade e necessidade de medicamentos e apoiando processos de redistribuição entre serviços. Ao estruturar a comunicação e viabilizar a redistribuição de medicamentos, a plataforma contribui para o uso mais eficiente de recursos públicos e privados, com impacto direto na sustentabilidade e no acesso à assistência farmacêutica.
- Open Access
- 21 August 2026
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 48 (6) , 2201-2211
Instruments for assessing healthcare professionals’ knowledge, attitudes and practices regarding deprescribing: a scoping review
Introduction: Deprescribing is a multiprofessional process which aims to optimize medication use and improve patient safety, in which healthcare professionals' knowledge, attitudes, and practices (KAP) play a central role. The instruments used to assess KAP among nurses, pharmacists and physicians remain poorly characterised in terms of scope and measurement quality. Aim: To map and characterize the instruments used to assess healthcare professionals’ knowledge, attitudes, and practices regarding deprescribing. Method: A scoping review was conducted following Joaassess healthcaree (JBI) methodology and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Primary studies were eligible if they involved nurses, pharmacists or physicians and applied any instrument assessing KAP related to deprescribing, individually or in combination, regardless of setting or country. Nine electronic databases were searched, including two grey literature sources were searched from inception to September 2024, without restrictions on language or publication date using terms related to nurses, pharmacists, physicians, deprescribing, surveys and questionnaires, and health knowledge, attitudes, and practice Study selection and data charting were performed independently by three pairs of reviewers using a standardised extraction form capturing study characteristics, instrument details, KAP domains assessed, and reported measurement properties. Data was synthesised using descriptive statistics and narrative analysis. The review protocol was registered on the Open Science Framework. Results: Of the 3,821 records screened, 49 met the inclusion criteria. Over two-thirds of the included studies were published since 2020 (n = 33, 67.3%). The evidence base was concentrated in high-income countries (n = 36/46, 78.0%; three multi-country studies were not classified by income level), particularly in the Europe and Central Asia region (n = 19, 41.0%), and most often focused solely on physicians, while studies simultaneously involving all three professional groups (physicians, pharmacists, and nurses) were less frequent (n = 8, 16.0%). Instruments commonly assessed multiple KAP domains, especially knowledge, attitudes, and practices combined (n = 12, 30.0%), whereas evidence on psychometric properties was reported in only a minority of studies (n = 13, 26.5%), among these, internal consistency and content validity were the pair most frequently reported together (n = 4, 31.0%). Conclusion: Instruments assessing healthcare professionals’ KAP regarding deprescribing remain limited in scope and psychometric robustness. Expanding interprofessional coverage and strengthening validation efforts are key priorities for advancing research in this field.
- 21 August 2026
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 48 (6) , 2201-2211
Open AccessInstruments for assessing healthcare professionals’ knowledge, attitudes and practices regarding deprescribing: a scoping review
Introduction: Deprescribing is a multiprofessional process which aims to optimize medication use and improve patient safety, in which healthcare professionals' knowledge, attitudes, and practices (KAP) play a central role. The instruments used to assess KAP among nurses, pharmacists and physicians remain poorly characterised in terms of scope and measurement quality. Aim: To map and characterize the instruments used to assess healthcare professionals’ knowledge, attitudes, and practices regarding deprescribing. Method: A scoping review was conducted following Joaassess healthcaree (JBI) methodology and reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). Primary studies were eligible if they involved nurses, pharmacists or physicians and applied any instrument assessing KAP related to deprescribing, individually or in combination, regardless of setting or country. Nine electronic databases were searched, including two grey literature sources were searched from inception to September 2024, without restrictions on language or publication date using terms related to nurses, pharmacists, physicians, deprescribing, surveys and questionnaires, and health knowledge, attitudes, and practice Study selection and data charting were performed independently by three pairs of reviewers using a standardised extraction form capturing study characteristics, instrument details, KAP domains assessed, and reported measurement properties. Data was synthesised using descriptive statistics and narrative analysis. The review protocol was registered on the Open Science Framework. Results: Of the 3,821 records screened, 49 met the inclusion criteria. Over two-thirds of the included studies were published since 2020 (n = 33, 67.3%). The evidence base was concentrated in high-income countries (n = 36/46, 78.0%; three multi-country studies were not classified by income level), particularly in the Europe and Central Asia region (n = 19, 41.0%), and most often focused solely on physicians, while studies simultaneously involving all three professional groups (physicians, pharmacists, and nurses) were less frequent (n = 8, 16.0%). Instruments commonly assessed multiple KAP domains, especially knowledge, attitudes, and practices combined (n = 12, 30.0%), whereas evidence on psychometric properties was reported in only a minority of studies (n = 13, 26.5%), among these, internal consistency and content validity were the pair most frequently reported together (n = 4, 31.0%). Conclusion: Instruments assessing healthcare professionals’ KAP regarding deprescribing remain limited in scope and psychometric robustness. Expanding interprofessional coverage and strengthening validation efforts are key priorities for advancing research in this field.
- Open Access
- 24 May 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (6)
Efficacy and Safety of Second‐Generation Antipsychotics for Irritability Associated With Autism Spectrum Disorder: A Systematic Review and Network Meta‐Analysis
Objective: To assess, by a systematic review and network meta‐analysis, the comparative efficacy and safety of second‐generation antipsychotics in managing aggressive behavior associated with autism spectrum disorder in children and adults. Methods: Searches were conducted in MEDLINE, Embase, CENTRAL, PsycINFO, LILACS, CINAHL, trial registries, and grey literature from database inception to July 2025. Randomized controlled trials comparing second‐generation antipsychotics with placebo or other antipsychotics in individuals with autism were included. Outcomes were irritability (Aberrant Behavior Checklist–Irritability subscale—ABC‐I), global clinical impression (CGI), treatment discontinuation, and central nervous system–related adverse events. Data extraction and risk‐of‐bias assessment (RoB 2.0) were performed independently. Certainty of evidence was evaluated using CINeMA. Frequentist random‐effects network meta‐analyses reported mean differences (MD) or relative risks (RR) with 95% confidence intervals (CI). Incoherence and small‐study effects were assessed. Results: Fourteen trials including 1195 children with autism were analyzed; no studies involved adults. Aripiprazole at low (MD: −5.83; 95% CI: −8.63, −3.02), recommended (MD: −5.69; 95% CI: −7.34, −4.04), and high doses (MD: −6.91; 95% CI: −10.04, −3.77), and recommended‐dose risperidone (MD: −6.91; 95% CI: −9.52, −4.31) reduced irritability versus placebo; lurasidone showed no benefit. No significant differences were observed for CGI. Recommended‐dose aripiprazole (RR: 0.57; 95% CI: 0.36, 0.90) and risperidone (RR: 0.29; 95% CI: 0.10, 0.83) lowered discontinuation risk. Both drugs increased sedation, drowsiness, and tremor. Evidence certainty ranged from very low to moderate. Head‐to‐head comparisons were inconclusive, and evidence was limited by the absence of adult studies and the small number of trials for some comparisons. Conclusions: Risperidone and aripiprazole reduce irritability in pediatric autism but increase sedation, drowsiness, and tremor. No robust differences between active treatments were identified. PROSPERO Registration: 42022353795
- 24 May 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (6)
Open AccessEfficacy and Safety of Second‐Generation Antipsychotics for Irritability Associated With Autism Spectrum Disorder: A Systematic Review and Network Meta‐Analysis
Objective: To assess, by a systematic review and network meta‐analysis, the comparative efficacy and safety of second‐generation antipsychotics in managing aggressive behavior associated with autism spectrum disorder in children and adults. Methods: Searches were conducted in MEDLINE, Embase, CENTRAL, PsycINFO, LILACS, CINAHL, trial registries, and grey literature from database inception to July 2025. Randomized controlled trials comparing second‐generation antipsychotics with placebo or other antipsychotics in individuals with autism were included. Outcomes were irritability (Aberrant Behavior Checklist–Irritability subscale—ABC‐I), global clinical impression (CGI), treatment discontinuation, and central nervous system–related adverse events. Data extraction and risk‐of‐bias assessment (RoB 2.0) were performed independently. Certainty of evidence was evaluated using CINeMA. Frequentist random‐effects network meta‐analyses reported mean differences (MD) or relative risks (RR) with 95% confidence intervals (CI). Incoherence and small‐study effects were assessed. Results: Fourteen trials including 1195 children with autism were analyzed; no studies involved adults. Aripiprazole at low (MD: −5.83; 95% CI: −8.63, −3.02), recommended (MD: −5.69; 95% CI: −7.34, −4.04), and high doses (MD: −6.91; 95% CI: −10.04, −3.77), and recommended‐dose risperidone (MD: −6.91; 95% CI: −9.52, −4.31) reduced irritability versus placebo; lurasidone showed no benefit. No significant differences were observed for CGI. Recommended‐dose aripiprazole (RR: 0.57; 95% CI: 0.36, 0.90) and risperidone (RR: 0.29; 95% CI: 0.10, 0.83) lowered discontinuation risk. Both drugs increased sedation, drowsiness, and tremor. Evidence certainty ranged from very low to moderate. Head‐to‐head comparisons were inconclusive, and evidence was limited by the absence of adult studies and the small number of trials for some comparisons. Conclusions: Risperidone and aripiprazole reduce irritability in pediatric autism but increase sedation, drowsiness, and tremor. No robust differences between active treatments were identified. PROSPERO Registration: 42022353795
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Reviewed article: Carvalho, SMO; Andrade, JX; Nascimento, FF; Rodrigues, MTP; Mascarenhas, MDM. Temporal trends in acquired syphilis detection, hospitalizations, and mortality: a time series analysis, Brazil, 2011-2023. Epidemol Serv Saude. 2026:35;e20251388
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Open AccessReviewed article: Carvalho, SMO; Andrade, JX; Nascimento, FF; Rodrigues, MTP; Mascarenhas, MDM. Temporal trends in acquired syphilis detection, hospitalizations, and mortality: a time series analysis, Brazil, 2011-2023. Epidemol Serv Saude. 2026:35;e20251388
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Reviewed article: Proença R, Nunes CCMN, Romano APM, Silva CP, Frank CHM, Moraes FS, Gonçalves FSS, Bandeira GS, Rodrigues IA, Cavalcante JR, Fonseca JLP, Silva LC, Duarte MMS, Maia MA, Mello MS, Nascimento MP, Nienov OH, Costa POM, Martins RCC, Melo SA, Ferreira VP, Casaroto VS, Freitas DRC, Almeida TVR, Garcia MHO, Barreira Filho EB. National Guidelines for Public Health Emergency Surveillance within the Brazilian Unified Health System. Epidemiol Serv Saude. 2026:35;e20260071
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Open AccessReviewed article: Proença R, Nunes CCMN, Romano APM, Silva CP, Frank CHM, Moraes FS, Gonçalves FSS, Bandeira GS, Rodrigues IA, Cavalcante JR, Fonseca JLP, Silva LC, Duarte MMS, Maia MA, Mello MS, Nascimento MP, Nienov OH, Costa POM, Martins RCC, Melo SA, Ferreira VP, Casaroto VS, Freitas DRC, Almeida TVR, Garcia MHO, Barreira Filho EB. National Guidelines for Public Health Emergency Surveillance within the Brazilian Unified Health System. Epidemiol Serv Saude. 2026:35;e20260071
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Tonaco LAB, Felisbino-Mendes MS, Moreira AD, Romeiro AMS, Silveira EA, Souza MJS, Velásquez-Meléndez G. Performance of anthropometric indices in early detection of diabetes and prediabetes in the Brazilian population: a cross-sectional study, Brazil, 2013. Epidemiol Serv Saude. 2026:35;e20240606.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Open AccessTonaco LAB, Felisbino-Mendes MS, Moreira AD, Romeiro AMS, Silveira EA, Souza MJS, Velásquez-Meléndez G. Performance of anthropometric indices in early detection of diabetes and prediabetes in the Brazilian population: a cross-sectional study, Brazil, 2013. Epidemiol Serv Saude. 2026:35;e20240606.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Reviewed article: Neto LLS, Campos EM, Pontes RJS, Pessoa VM. Common mental disorders and care provided by the Health Care Network for the rural population: a cross-sectional study, Novo Oriente and Icapuí, Ceará, Brazil, 2020. Epidemiol Serv Saude. 2026:35;e20250540
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Open AccessReviewed article: Neto LLS, Campos EM, Pontes RJS, Pessoa VM. Common mental disorders and care provided by the Health Care Network for the rural population: a cross-sectional study, Novo Oriente and Icapuí, Ceará, Brazil, 2020. Epidemiol Serv Saude. 2026:35;e20250540
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35, e20263002
Twenty five years of the Training Program in Epidemiology Applied to the Unified Health System Services: contributions of field epidemiology to health surveillance in Brazil
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35, e20263002
Open AccessTwenty five years of the Training Program in Epidemiology Applied to the Unified Health System Services: contributions of field epidemiology to health surveillance in Brazil
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Reviewed article: Lindolfo L, Correa FM, Horta MC, Gradela A. Riskareas and social determinants of health: a longitudinal epidemiological studywith temporal analysis of visceral leishmaniasis in Mirandiba and Salgueiro,2013-2022. Epidemiol Serv Saude. 2026:35;e20250292.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Epidemiologia e Serviços de Saúde
- Vol. 35
Open AccessReviewed article: Lindolfo L, Correa FM, Horta MC, Gradela A. Riskareas and social determinants of health: a longitudinal epidemiological studywith temporal analysis of visceral leishmaniasis in Mirandiba and Salgueiro,2013-2022. Epidemiol Serv Saude. 2026:35;e20250292.